COVID-19门诊管理:快速证据综述
本文综述了COVID-19门诊管理的快速证据,指出变异株特征影响诊断与治疗,应鼓励6个月及以上人群接种疫苗以降低发病率、住院和死亡,并考虑将奈玛特韦/利托那韦作为 eligible 患者的一线治疗。
要点
- 变异株特征影响诊断与治疗策略。
- 6个月及以上人群应接种疫苗,可减少住院和死亡。
- eligible 患者可考虑奈玛特韦/利托那韦一线治疗。
核心结论
- COVID-19变异株特征决定诊断和治疗方面,疫苗有效降低发病率、住院和死亡,eligible患者可考虑奈玛特韦/利托那韦一线治疗。
研究设计与样本
- 快速证据综述,来自Am Fam Physician。
主要发现
- incubation period、传播性、免疫逃逸和治疗效果因变异株而异。
- 多种检测方法存在,最佳策略取决于临床场景、检测敏感性、周转时间和标本采集专业性。
- 美国有三种疫苗可用,所有6个月及以上人群应鼓励接种。
- 疫苗接种可降低COVID-19发病率、住院和死亡,也可能减少 post-acute sequelae(长期COVID)的发生率。
- 长期健康影响正在研究中。
关键数值与推荐
- 所有6个月及以上人群应鼓励接种COVID-19疫苗。
- eligible患者可考虑奈玛特韦/利托那韦作为一线治疗,除非存在后勤或供应限制。
- 资格确定可参考NIH指南和当地医疗伙伴资源。
临床怎么用
- 根据变异株特征调整诊断和治疗策略。
- 鼓励6个月及以上人群接种疫苗。
- 对eligible的COVID-19患者考虑奈玛特韦/利托那韦一线治疗。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
New COVID-19 variants of concern continue to develop. Incubation period, transmissibility, immune escape, and treatment effectiveness differ by variants of concern. Physicians should be aware that the characteristics of the predominant variants of concern determine aspects of diagnosis and treatment. Multiple testing modalities exist; the most appropriate testing strategy varies depending on the clinical scenario, with factors of test sensitivity, turnaround time, and the expertise required for specimen collection. Three types of vaccines are available in the United States, and all people six months and older should be encouraged to receive one because vaccination is effective in reducing the incidence of and hospitalizations and deaths associated with COVID-19. Vaccination may also reduce the incidence of post-acute sequelae of SARS-CoV-2 infection (i.e., long COVID). Consider medications, such as nirmatrelvir/ritonavir, as first-line treatment for eligible patients diagnosed with COVID-19 unless logistical or supply constraints occur. National Institutes of Health guidelines and local health care partner resources can be used to determine eligibility. Long-term health effects of having COVID-19 are under investigation.
引用
- Cheng AM, Dollar E, Angier H, et al. Outpatient Management of COVID-19: Rapid Evidence Review. Am Fam Physician. 2023. PMID: 37054413
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。